Endocanna Health receives the first federal patent for its groundbreaking DNA test and software platform that reduces the risk of emergency room visits from cannabis therapies and productsEndocanna's newly patented platform aims to revolutionize the precision of cannabis therapy BURBANK, Calif., June 5, 2023 /PRNewswire/ -- Endocanna Health ("Endocanna"), the industry leader in endocannabinoid system genomic testing, announces the issuance of a first-of-its-kind U.S. patent for its DNA test that

NEW YORK, June 5, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that on June 2, 2023, it completed a private placement of 22,000,000 class A ordinary shares and warrants to purchase

WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the promotion of Dr. Shengfang Jin to President and Chief Executive Officer, effective immediately. Dr. Jin has more than 25 years of biotech and pharma leadership experience in oncology and other disease therapeutics development. "On behalf of ENSEM's Board of Directors, we are delighted to announce the promotion of Dr. Jin,

Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government research including comprehensive single T Cell profiling, for precision immunotherapy translational research and accelerated development EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of the Beacon Quest™ optofluidic system, with Opto® T Cell Prof

Baltimore-based healthcare research, strategy and marketing firm continues to achieve national recognition for its agency talent and communications expertise BALTIMORE, June 5, 2023 /PRNewswire/ -- Sage Growth Partners (SGP), a Baltimore-based healthcare research, strategy, and marketing firm, is pleased to announce that its work and ongoing partnership with ProgenyHealth has been nationally recognized for Best Use of Media Relations in the annual 2023 HITMC awards. The annual HITMC (Healthcare

EMERYVILLE, Calif., June 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers ("PwC") and established a subcommittee of the Board (the "Restructuring Committee"), made up of three independent dir

任何一个看似突然的企业战略决策，实际都是深思熟虑的结果。度过了饱受争议的2022年，和铂医药迎来了增长超8倍的营收。创始人王劲松认为，这离不开前瞻性的布局。他直言，内部讨论最多的问题便是“怎么去创新，怎么在更高要求的创新下去突破”。“提效、创新。只有创新才能有优势，这个优势才会有差异，才会创造更多的价值。”在整个产业技术创新加快的节奏中，如何在局部领域实现差异化优势，从而保持领先地位，与更前沿的技术实现更好结合，拓展技术平台的应用场景，做一个创新型的国际级别公司，这是和铂医药内部一直在思考的问题。无一例外，和铂医药也面对着一些共性的挑战：一是不管在什么样的市场环境下，对于创新的需求不仅没有减少，反而增强，不少Biotech需更聚焦有革命性的技术创新和应用场景增加；二是对于能够给患者带来巨大获益的产品管线项目，Biotech需集中资源使其更快、更高效地往前推进,让它更接近市场、临床以及患者。创新能力不仅是技术创新，更重要的是产品创新、执行力和商业模式的创新。创立:成为排头兵从“追赶”到“引领”，从难聚焦到聚焦，和铂医药双抗技术平台正在冲击全球第一梯队。王劲松庆幸，成立之初，坚持对标国际创

2023年6月20日，上海将举办2023中俄医药合作论坛，俄罗斯联邦工业和贸易部、中国监管部门（TBA）和俄罗斯卫生部的代表将参加本次活动。该活动旨在加强中国和俄罗斯在开展临床试验、市场授权和药品进出口方面的全面战略合作。会议将包括但不限于以下内容：俄罗斯的上市许可研发和临床试验法规GMP检查要求俄罗斯和中国制药公司之间的合作机会海外制药业的商业价值中国制药公司可以免费参加此次活动。活动注册只需在文尾扫描二维码报名即可。关键发言人Ekaterina Prieszheva (叶卡捷琳娜·普里什耶娃) 俄罗斯联邦工业和贸易部副部长 俄罗斯联邦工业和贸易部   Timofey Nizhegorodsev (提莫费·尼日戈罗德采夫) 副主任 俄罗斯联邦联邦反垄断局Valentina Kosenko (瓦伦蒂娜·科森科) 代理总裁 俄罗斯卫生部医药产品专家评估科学中心Vitaliy Omelyanovskiy (维塔利·奥梅利亚诺夫斯基) 总经理 俄罗斯联邦卫生部医疗保健质量评估和控制中心Roman Ivanov (罗曼·伊万诺夫) 转化医学科学中心主任，科技发展副校长 天狼星科技大学日程安排2

科伦博泰首次呈交招股书就通过了港交所聆讯，而过去一年大多成功通过18A登陆港交所的Biotech都经过数次更新，2023年的资本市场是否已开始解冻？18A红利又回来了吗？6月4日，港交所官网显示科伦博泰已呈交聆讯后资料，这意味着科伦博泰已通过聆讯，即将登陆港交所，港交所也或将在近期迎来2023年第二家通过18A规则上市的生物制药公司。值得注意的是，科伦博泰也是2022年以来为数不多首次呈交招股书就通过聆讯的未盈利生物制药公司。（图片来源：港交所官网）过去一年多，资本寒冬的触角绊住了生物技术公司登陆二级市场的步伐。E药经理人统计，2022年港股通过18A规则上市公司数量不足申请数量的三分之一，而2021年以前，二者数量几乎相差无几。有观点认为这与港股市场的流动性差不无关系，上市即破发、一二级市场估值倒挂犹如一道铁门，让生物技术公司们望而却步。同时，科创板鼓励硬科技的新政频出，吸引大批创新医疗器械公司奔赴，无论是流动性还是估值都更胜一筹。作为国内首个开放未盈利生物技术公司登陆的股票市场，港股18A红利真的不再了吗？失效E药经理人根据港交所公开信息统计，2018年港交所推出第18A章上市规则

更上层楼扬帆领航，乘势而上再创辉煌“北大医学&北大光华医疗健康产业领航计划”项目第三期招生重磅开启！2023年10月，相聚北大，吹响领航号角，共谱行业华章。 融合“顶尖医学+前沿商学”跨界优势，打造医疗健康领域产业融合生态。“北大医学&北大光华医疗健康产业领航计划”顶级师资队伍不断扩容，课程体系持续优化，领军校友圈层日益完善，项目已成为了解国内外大健康产业发展的前沿窗口和培养未来产业人才的重要平台。加入项目，把握医疗大健康行业趋势，正当其时！厚道敢当   强强联合传承北医“厚道”精神，弘扬光华“敢当”品格。“北大医学&北大光华医疗健康产业领航计划”项目不仅汇集北大代表性优势学科资源，更融汇双方“厚道”、“敢当”的精神气质，打造拥有独特底蕴传承和精神内涵的品牌项目。点击视频，观看课程精彩瞬间顶级师资  品质引领北京大学医学部+光华管理学院携手，顶尖医学+前沿商学跨界合作，一站式汇集两院院士、科研和临床一线专家学者，产业政策权威专家，医疗健康产业领军人物等，全方位高品质输出，深度剖析产业趋势和方向，密切关注全球临床及实验室前沿动向，全景洞察全球医疗大健康产业发展。前沿课程  全面覆盖九大模